MX9708165A - Regulacionde la s-adenosil metionina de trayectos o secuencias metabolicas y su uso en el diagnostico y la terapia. - Google Patents
Regulacionde la s-adenosil metionina de trayectos o secuencias metabolicas y su uso en el diagnostico y la terapia.Info
- Publication number
- MX9708165A MX9708165A MX9708165A MX9708165A MX9708165A MX 9708165 A MX9708165 A MX 9708165A MX 9708165 A MX9708165 A MX 9708165A MX 9708165 A MX9708165 A MX 9708165A MX 9708165 A MX9708165 A MX 9708165A
- Authority
- MX
- Mexico
- Prior art keywords
- pathways
- sam
- metabolic pathways
- disease
- diagnosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Psychiatry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
Abstract
Un nuevo paradigma de la enfermedad se centra alrededor de las secuencias metabolicas de la S-adenosil-L-medicinan (SAM), los intermediarios de estas secuencias y otras secuencias metabolicas influenciadas por las secuencias de la SAM. Se proporcionan métodos para analizar o modular las secuencias de la SAM asociadas con una enfermedad o condicion.Tales métodos permiten la identificacion y utilizacion de protocolos de diagnostico y terapéuticos y agentes para tales estados de enfermedades y condiciones.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/428,963 US6020139A (en) | 1995-04-25 | 1995-04-25 | S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy |
US47644795A | 1995-06-07 | 1995-06-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9708165A true MX9708165A (es) | 1998-06-28 |
Family
ID=27027980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9708165A MX9708165A (es) | 1995-04-25 | 1997-10-23 | Regulacionde la s-adenosil metionina de trayectos o secuencias metabolicas y su uso en el diagnostico y la terapia. |
Country Status (7)
Country | Link |
---|---|
US (1) | US6596701B1 (es) |
EP (2) | EP1221615A2 (es) |
JP (1) | JPH11506426A (es) |
AU (1) | AU721067B2 (es) |
CA (1) | CA2217696A1 (es) |
MX (1) | MX9708165A (es) |
WO (1) | WO1996033703A2 (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6255295B1 (en) * | 1996-12-23 | 2001-07-03 | Nutramax Laboratories, Inc. | Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine composition for the protection, treatment, repair, and reduction of inflammation of connective tissue |
US20020006913A1 (en) * | 1997-11-04 | 2002-01-17 | Von Borstel Reid W. | Antimutagenic compositions for treatment and prevention of photodamage to skin |
EP1158447A1 (en) * | 2000-05-26 | 2001-11-28 | GMD- Forschungszentrum Informationstechnik GmbH | Method for evaluating states of biological systems |
IT1317920B1 (it) * | 2000-10-20 | 2003-07-15 | Univ Roma | S-adenosilmetionina e suoi derivati per il trattamento e laprevenzione della malattia di alzheimer. |
US7319945B1 (en) * | 2000-11-10 | 2008-01-15 | California Institute Of Technology | Automated methods for simulating a biological network |
DE10100121A1 (de) * | 2001-01-03 | 2002-08-01 | Henkel Kgaa | Verfahren zur Bestimmung des Hautstreß oder der Hautalterung in vitro |
EP1302115A1 (fr) * | 2001-10-16 | 2003-04-16 | Societe Des Produits Nestle S.A. | Utilisation de cystathionine |
AU2002343609B2 (en) * | 2001-11-16 | 2008-12-11 | Als Therapy Development Foundation, Inc. | Treatment of neurodegenerative disorders through the modulation of the polyamine pathway |
US7598278B2 (en) | 2002-04-11 | 2009-10-06 | L'oreal | Administration of pyridinedicarboxylic acid compounds for stimulating or inducing the growth of human keratinous fibers and/or arresting their loss |
US7485307B2 (en) * | 2002-06-17 | 2009-02-03 | The Regents Of The University Of Colorado | Human cystathionine β-synthase variants and methods of production thereof |
WO2004065542A2 (en) * | 2002-12-30 | 2004-08-05 | Exelixis, Inc. | MAT2As AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
US20040181167A1 (en) * | 2003-03-13 | 2004-09-16 | Carney Fiona Patricia | Method and kits for monitoring women's health |
US8173618B2 (en) * | 2003-07-25 | 2012-05-08 | University Of Massachusetts | Formulations for reducing neuronal degeneration |
EP1711197A4 (en) * | 2003-12-23 | 2008-11-05 | Musc Found For Res Dev | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES OR DISORDERS |
WO2006079212A1 (en) * | 2005-01-26 | 2006-08-03 | Diamedica Inc. | Use of s-adenosylmethionme, vitamin e, and vitamin c for the treatment of oxidative liver injury or insulin resistance |
US20070053970A1 (en) * | 2005-05-25 | 2007-03-08 | Guilford F T | Liposomal formulation for oral administration of glutathione (reduced) and/or methylcobalamine for diseases related to glutathione deficiency and deficiency of the methionine remethylation pathway |
US8637321B2 (en) * | 2005-10-24 | 2014-01-28 | Duke University | Lipidomics approaches for central nervous system disorders |
US8137977B2 (en) * | 2006-04-24 | 2012-03-20 | Children's Hospital & Research Center At Oakland | Lipidomic approaches to determining drug response phenotypes in cardiovascular disease |
EP2127656A4 (en) | 2006-12-20 | 2010-03-03 | Landsteiner Scient S A De C V | COMPOSITIONS OF RISEDRONATE AND VITAMIN D3 |
CN101677543A (zh) * | 2007-01-31 | 2010-03-24 | 甲基化物科学国际有限公司 | S-腺苷甲硫氨酸的延时释放药物制剂 |
US20090197824A1 (en) * | 2008-01-31 | 2009-08-06 | Methylation Sciences International Srl | Extended Release Pharmaceutical Formulations of S-Adenosylmethionine |
US20090088404A1 (en) * | 2007-01-31 | 2009-04-02 | Methylation Sciences International Srl | Extended Release Pharmaceutical Formulations of S-Adenosylmethionine |
US20080255098A1 (en) | 2007-04-13 | 2008-10-16 | Robert Dunn | Compositions and Methods for Treatment of Psychiatric Disorders |
US8597640B2 (en) * | 2007-10-31 | 2013-12-03 | University Of Massachusetts Lowell | Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging |
CN104557914A (zh) * | 2008-09-26 | 2015-04-29 | 新加坡科技研究局 | 3-脱氮瓶菌素衍生物 |
US8329208B2 (en) * | 2009-07-28 | 2012-12-11 | Methylation Sciences International Srl | Pharmacokinetics of S-adenosylmethionine formulations |
US20110027342A1 (en) * | 2009-07-28 | 2011-02-03 | Msi Methylation Sciences, Inc. | S-adenosylmethionine formulations with enhanced bioavailability |
CA2825428C (en) | 2010-02-12 | 2022-06-14 | Alexander Vuckovic, M.D., Llc | Compositions and methods for treating depression |
US9675678B2 (en) | 2013-01-29 | 2017-06-13 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for treatment of homocystinuria |
FR3002139B1 (fr) * | 2013-02-21 | 2015-06-19 | Amabiotics | Utilisation cosmetique de la queuine |
GB201417163D0 (en) | 2014-09-29 | 2014-11-12 | Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases |
GB201417165D0 (en) * | 2014-09-29 | 2014-11-12 | Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin | Treatments for Autoimmune Disease |
FR3030248B1 (fr) | 2014-12-22 | 2018-03-23 | L'oreal | Association derive d'acide pyridine-dicarboxylique/agent anti-oxydant particulier |
CN108472277A (zh) | 2015-11-09 | 2018-08-31 | 科罗拉多州立大学董事会法人团体 | 用于治疗高胱氨酸尿症的组合物和方法 |
SG11201811755PA (en) * | 2016-07-01 | 2019-01-30 | Agency Science Tech & Res | A wound healing composition |
EP3290039B1 (en) * | 2016-08-30 | 2020-03-25 | Amabiotics | Compounds for treating diseases associated with a mitochondrial dysfonction |
AU2017397463B2 (en) | 2016-11-03 | 2022-01-06 | HedoniaUSA, Inc. | Compositions and methods for treating depression |
EP3612214A4 (en) | 2017-04-17 | 2021-01-20 | The Regents of the University of Colorado, A Body Corporate | OPTIMIZATION OF ALTERNATIVE ENZYMOTHERAPY FOR THE TREATMENT OF HOMOCYSTINURIA |
KR20210005848A (ko) * | 2018-03-07 | 2021-01-15 | 아마바이오틱스 | 알츠하이머병을 치료하기 위한 화합물 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2330902A1 (de) * | 1973-06-18 | 1975-03-20 | Helmut Dr Med Zander | Heilungsfoerderndes und vorbeugendes, zur aeusserlichen oertlichen anwendung auf der haut und im auge fuer mensch und tier bestimmtes arznei- bzw. hautpflegemittel |
US4373097A (en) | 1981-04-27 | 1983-02-08 | Bioresearch S.R.L. | Process for preparing adenosine derivatives of anti-inflammatory and analgesic activity |
IT1137640B (it) | 1981-08-24 | 1986-09-10 | Bioresearch Srl | Sali stabili della s-adenosilmetionina,processo per la loro preparazione e composizioni terapeutiche che li comprendono come principio attivo |
US4499072A (en) | 1982-11-29 | 1985-02-12 | Merrell Dow Pharmaceuticals Inc. | Process for treating diseases with ODC inhibitors |
GB8330969D0 (en) * | 1983-11-21 | 1983-12-29 | Wellcome Found | Promoting healing |
US5409904A (en) * | 1984-11-13 | 1995-04-25 | Alcon Laboratories, Inc. | Hyaluronic acid compositions and methods |
CA1295998C (en) | 1985-07-29 | 1992-02-18 | Sai P. Sunkara | Nucleosides and their use as antineoplastic agents |
US4772591A (en) * | 1985-09-25 | 1988-09-20 | Peritain, Ltd. | Method for accelerated wound healing |
US5236952A (en) | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
JPS6339813A (ja) * | 1986-08-05 | 1988-02-20 | Eisai Co Ltd | 創傷治療剤 |
WO1988004927A1 (en) * | 1986-12-31 | 1988-07-14 | Davirand, Inc. | Compositions and formulations containing folic acid, method of treating tissue with folic acid and method for preparing compositions and formulations of folic acid |
US4871718A (en) * | 1987-12-29 | 1989-10-03 | Raymond A. Roncari | Composition of matter for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair |
US4971986A (en) | 1988-03-25 | 1990-11-20 | Ciba-Geigy Corporation | Arylhydrazones useful as SAMDC inhibitors |
EP0358536B1 (en) | 1988-07-21 | 1996-05-08 | Merrell Pharmaceuticals Inc. | Novel S-adenosyl methionine decarboxylase inhibitors |
US5043268A (en) | 1990-05-04 | 1991-08-27 | The Trustees Of Princeton University | Substrates and inhibitors for prenyl cysteine methyltransferase enzymes |
ATE159428T1 (de) | 1990-08-14 | 1997-11-15 | Joseph H Handelman | Enzymatische änderung des haarwuchses |
US5180714A (en) | 1990-10-31 | 1993-01-19 | Health Research, Inc. | Adenosine compounds for the treatment of diseases caused by parasitic protozoa |
CA2094341A1 (en) * | 1992-04-28 | 1993-10-29 | Carl W. Porter | Methods for the use of spermidine/spermine n1-acetyltransferase as a prognostic indicator and/or tumor response marker |
US5264355A (en) | 1992-07-02 | 1993-11-23 | Merck & Co., Inc. | Methlating enzyme from streptomyces MA6858 |
US5428063A (en) | 1994-04-11 | 1995-06-27 | Board Of Regents Of The University Of Nebraska | Use of betaine as a hepatic generator of S-adenosylmethionine and as a protective agent against hepatotoxicity |
JP3483988B2 (ja) * | 1995-06-01 | 2004-01-06 | 株式会社資生堂 | 皮膚外用剤 |
-
1996
- 1996-04-25 EP EP02005785A patent/EP1221615A2/en not_active Withdrawn
- 1996-04-25 CA CA002217696A patent/CA2217696A1/en active Pending
- 1996-04-25 AU AU57156/96A patent/AU721067B2/en not_active Ceased
- 1996-04-25 EP EP96915362A patent/EP0824345A4/en not_active Withdrawn
- 1996-04-25 WO PCT/US1996/005799 patent/WO1996033703A2/en not_active Application Discontinuation
- 1996-04-25 JP JP8532723A patent/JPH11506426A/ja not_active Ceased
- 1996-04-25 US US08/930,128 patent/US6596701B1/en not_active Expired - Fee Related
-
1997
- 1997-10-23 MX MX9708165A patent/MX9708165A/es unknown
Also Published As
Publication number | Publication date |
---|---|
JPH11506426A (ja) | 1999-06-08 |
EP0824345A1 (en) | 1998-02-25 |
WO1996033703A2 (en) | 1996-10-31 |
EP0824345A4 (en) | 1999-08-25 |
EP1221615A2 (en) | 2002-07-10 |
AU5715696A (en) | 1996-11-18 |
CA2217696A1 (en) | 1996-10-31 |
AU721067B2 (en) | 2000-06-22 |
US6596701B1 (en) | 2003-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9708165A (es) | Regulacionde la s-adenosil metionina de trayectos o secuencias metabolicas y su uso en el diagnostico y la terapia. | |
Karu | Photobiology of low-power laser effects | |
WO1995021927A3 (en) | Targeting gene therapy | |
WO2002099040A3 (en) | Igs as modifiers of the p53 pathway and methods of use | |
WO2002099041A3 (en) | Ces2s as modifiers of the p53 pathway and methods of use | |
Raaphorst | Thermal radiosensitization and repair inhibition in human melanoma cells: a comparison of survival and DNA double strand breaks | |
FRANKEN*, C. VAN BREE, JBA KIPP and GW BARENDSEN | Modification of potentially lethal damage in irradiated Chinese hamster V79 cells after incorporation of halogenated pyrimidines | |
Schafer | Narratives of the self. | |
WO1996015758A3 (en) | Methods for stimulating erythropoiesis using thrombopoietin | |
AU2003250938A1 (en) | Method for determination of thymidine kinase 1 activity and the use thereof | |
WO2000042166A3 (en) | Methods and compositions for monitoring cellular processing of epitope-tagged beta-amyloid precursor protein | |
WO2000020582A3 (en) | Gene replacement therapy for muscular dystrophy | |
Raben et al. | Kinetic and molecular species analyses of mitogen‐induced increases in diglycerides: Evidence for stimulated hydrolysis of phosphoinositides and phosphatidylcholine | |
Bembenek et al. | The effect of insulin on collagen production in isolated chondrosarcoma chondrocytes | |
Ludolph | Treatment of amyotrophic lateral sclerosis—What is the next step? | |
Gray | On the significance of influence and insight in the spectrum of psychoanalytic psychotherapies. | |
Ornstein | Multiple curative factors and processes in the psychoanalytic psychotherapies. | |
Rappaport | Traumatic time: The therapist's mourning. | |
Ogita et al. | Anti-aging effects of hydrophobic and hydrophilic components from immature pear fruits extract | |
Kilgren | Issues involved in the extraction of information from single-channel currents of cultured myotubes: A kinetic and stochastic analysis. | |
Markin et al. | Metabolism, intensity of lipid peroxidation and the antioxidant defense system in humans during chamber experiments with long-term isolation | |
HYDROPHOBIC et al. | An Approach to Identify New Pleiotropic Genetic Loci From Publicly Available Univariate GWAS Results | |
Maybaum et al. | Dynamics of Bromodeoxyuridine Incorporation into DNA of Squamous Carcinoma Cells During Mid and Late Logarithmic Growth | |
Bednar et al. | Marital and family therapy: Primary and unique considerations. | |
WO2005017118A3 (en) | Sulfs as modifiers of the beta catenin pathway and methods of use |